RxDoctor Payments Data

Rona McKenzie, MD

Internal Medicine · Fort Lauderdale, FLNPI 1851450530

Payments from drug & device makers

$3,558in general payments, 2019–2025

Across 150 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$703
  • Inari Medical, Inc.$422
  • Novo Nordisk$313
  • AbbVie$247
  • Pfizer$199
  • Lilly USA, LLC$174
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,545100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,558 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$107,414
Medicare patients
184
Services billed
1,074

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$54,110
FarxigaDapagliflozin Propanediol39$37,913
TradjentaLinagliptin30$32,512
EntrestoSacubitril/Valsartan36$28,290
JanuviaSitagliptin Phosphate20$27,236
OzempicSemaglutide23$20,104
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,620
XareltoRivaroxaban20$16,803
JanumetSitagliptin Phos/Metformin Hcl15$10,828
JardianceEmpagliflozin12$7,993
SymbicortBudesonide/Formoterol Fumarate14$5,260
Nifedipine ErNifedipine125$2,922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,885
Atorvastatin Calcium296$2,652
Albuterol Sulfate HfaAlbuterol Sulfate84$2,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$199$54,11061 claims
AstraZenecaFarxiga, Symbicort, Lokelma$703$43,96865 claims
Boehringer IngelheimTradjenta, Jardiance$75$40,50542 claims
MerckJanuvia, Janumet$118$38,06335 claims
NovartisEntresto$31$28,29036 claims
Novo NordiskOzempic$313$20,10423 claims
GSKTrelegy Ellipta$135$17,62022 claims
Johnson & JohnsonXarelto$125$16,80320 claims
AbbVieSynthroid$247$1,97915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Fort Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →